It will grow to $7.18 billion in 2029 at a compound annual growth rate (CAGR) of 15.6%.” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, July 4, 2025 /EINPresswire.com/ -- Save ...

Myriad Genetics’ first quarter results were met with a significant negative market reaction, reflecting investor concerns ...

Saturday Citations: Genetic toggles, undersea farmers and exploding rockets by Chris Packham, Phys.org edited by Gaby Clark, reviewed by Robert Egan Editors' notes ...

Genetic disease is believed to be linked to 41 percent of U.S. infants' deaths, while more than 2 million children have a genetic condition.

Looking Forward For families living with the daily realities of this genetic condition, the promise of a therapy that targets the underlying cause rather than just the symptoms could be life-changing.

Researchers have demonstrated a specific type of genetic variation in obsessive-compulsive disorder (OCD) for the first time using advanced DNA sequencing technology. The findings support previous ...

In a groundbreaking study, researchers have linked rare “de novo” genetic mutations—copy number variants (CNVs)—to pediatric obsessive-compulsive disorder (OCD). In a groundbreaking study, researchers ...

Moreover, Myriad Genetics was granted two new patents by the U.S. Patent and Trademark Office for bringing its MRD to market, building on three foundational patents awarded last year.

Review the current Myriad Genetics Inc (MYD:XDUS) dividend yield and history to decide if ATUS stock is the best investment for you.